Christine Mikail Cvijic is President & CFO at Neurogene Inc. (NGNE). They have made 4 open-market trades across 1 company since 2024, most recently 2026-07-07.
CIK 0001543663
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $492K since 2024, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NGNE | 84,040 | $2.0M |
| DNDN | 351,465 | — |
| Total | $2.0M |
Shares reported on the most recent Form 4, priced at the 2026-07-07 close. 1 holding could not be priced and is excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NGNE | SELL · 10b5-1 | 2026-07-06 | 2026-07-07 | $36.12 | $173K | +3.6% | -1.7% | -26.7% |
| NGNE | SELL · 10b5-1 | 2026-07-01 | 2026-07-02 | $34.71 | $167K | +10.9% | -8.0% | -21.8% |
| NGNE | SELL · 10b5-1 | 2026-05-06 | 2026-05-08 | $31.25 | $300K | -14.8% | -10.1% | +12.3% |
| NGNE | SELL | 2026-03-26 | 2026-03-30 | $21.62 | $111K | +4.4% | +35.8% | +65.3% |
| NGNE | SELL | 2026-03-13 | 2026-03-17 | $20.81 | $168K | -2.4% | +22.9% | +43.5% |
| NGNE | SELL · 10b5-1 | 2026-02-27 | 2026-03-03 | $25.11 | $121K | -3.1% | -6.8% | +24.5% |
| NGNE | SELL | 2025-03-13 | 2025-03-17 | $16.94 | $152K | -7.0% | -34.7% | +15.0% |
| NGNE | BUY | 2024-11-22 | 2024-11-25 | $20.48 | $492K | -8.7% | -7.2% | -36.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.